Overview of bladder cancer trials in the Radiation Therapy Oncology Group

Cancer

Volumn 97, Issue 8 SUPPL., 2003, Pages 2115-2119

  Shipley, William U ^a,b   Kaufman, Donald S ^a   Tester, William J ^a   Pilepich, Miljenko V ^a   Sandler, Howard M ^a  

^a RADIATION THERAPY ONCOLOGY GROUP   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bladder conservation; Chemotherapy; Overall survival; Radiation therapy; Radiation Therapy Oncology Group protocols

Indexed keywords

CISPLATIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONSERVATIVE TREATMENT; CYSTECTOMY; DRUG EFFICACY; HUMAN; METASTASIS; ORGAN PRESERVATION; PRIORITY JOURNAL; SIDE EFFECT; URINARY DIVERSION;

EID: 0037446128     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11282     Document Type: Conference Paper

References (20)

1. Zietman AL, Shipley WU, Kaufman DS. Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy. Ann Med. 2000;32:42.
2. Shipley WU, Prout GR Jr., Einstein AB Jr., et al. Treatment of invasive bladder cancer by cisplatin and irradiation in patients unsuited for surgery: a high success rate in clinical stage T2 tumors in a National Bladder Cancer Group trial. JAMA. 1987;258:931-935.
3. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of RTOG Phase III trial 8802. J Clin Oncol. 1996;14:119-126.
4. Shipley WU, Winter KA, Kaufman DS, et al. A Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of RTOG 89-03. J Clin Oncol. 1998;16:3576-3583.
5. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle-invading bladder cancer of RTOG-95-06: Phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 2000;5:471-476.
6. Hagan MP, Winter KA, Kaufman DS, et al. RTOG 9706: initial report of a Phase I/II trial of bladder conservation employing TURBT, accelerated irradiation sensitized with cisplatin followed by adjuvant MCV chemotherapy [abstract]. Int J Radiat Oncol Biol Phys. 2001;51:20.
7. Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys. 1993;25:783-790.
8. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combined modality treatment of invasive bladder cancer. N Engl J Med. 1993;329:1377-1382.
9. Moore MJ, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a Phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17:2876-2881.
10. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18:1921-1927.
11. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, cisplatin, vinblastine, doxorubicin, in advanced or metastatic bladder cancer: results of a large randomized, multinational, Phase III study. J Clin Oncol. 2000;17:3068-3077.
12. Roth BJ. The role of paclitaxel in the therapy of bladder cancer. Semin Oncol. 1995;22(5 Suppl 12):33-40.
13. Dreicer R, Manola J, Roth B, et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group (ECOG) study. J Clin Oncol. 2000;18:1058-1061.
14. Hussain MH, Glass TR, Forman J, et al. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a SWOG study. J Urol. 2001;165:56-61.
15. Natale RB, Grossman HB, Blumenstein B, et al. SWOG 87-10 (INT-0-080): randomized Phase III trial of neoadjuvant MVAC and cystectomy versus cystectomy alone in patients with locally advanced bladder cancer [abstract 3]. Proc Am Soc Clin Oncol. 2001;20.
16. Sternberg CN, Parmar MKB. Neoagent chemotherapy is not (yet) standard treatment for muscle-invasive bladder cancer. J Clin Oncol. 2001;19(Suppl):22-26.
17. International Collaboration of Trialists on behalf of the Medical Research Council. Advanced Bladder Cancer Working Party EORTC Genito-Urinary Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, and Club Urologico Espanol de Tratamiento Oncologico (CUETO) Group. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: a randomized controlled trial. Lancet. 1999;354:533-540.
18. Bellmunt J, Guillem V, Paz-Area L, et al. Phase I/II study of paclitaxel, cisplatin and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol. 2000; 18:3247-3255.
19. de Wit R. Overview of bladder cancer trials in the European Organization for Research and Treatment of Cancer. Cancer. This issue.
20. Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor (EGFR) is associated with improved outcome in muscle-invading bladder cancer: an RTOG study [abstract 713]. Proc Am Soc Clin Oncol. 2002; 21:179a.